eprintid: 87757
rev_number: 2
eprint_status: archive
userid: 1
dir: disk0/00/08/77/57
datestamp: 2026-05-26 16:23:14
lastmod: 2026-06-14 11:00:40
status_changed: 2026-05-26 16:23:14
type: article
metadata_visibility: show
sword_depositor: 1
creators_name: Nazeem, Mehak
creators_name: Haleema Iqbal, 
creators_name: Nisar, Nayab
creators_name: Saifullah, 
title: SGLT2 INHIBITORS BEYOND DIABETES A RETROSPECTIVE AUDIT OF PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
ispublished: pub
note: Imported from Universal Publishings (OAI id oai:ojs.pkp.sfu.ca:article/18316)
abstract: Heart failure with preserved ejection fraction (HFpEF) constitutes a substantial and increasing proportion of heart failure cases worldwide, with historically limited evidence-based therapeutic options. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, initially developed for the management of type 2 diabetes mellitus, have demonstrated significant cardiovascular benefits, including reductions in heart failure hospitalizations and improvement in functional outcomes, irrespective of glycemic status. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes. 
date: 2026-05-10
date_type: published
publisher: Research Science and Innovation House
official_url: https://universalpublishings.com/index.php/siad/article/view/18316
id_number: oai:ojs.pkp.sfu.ca:article/18316
full_text_status: public
publication: SYNAPSES: INSIGHTS ACROSS THE DISCIPLINES
citation:   Nazeem, Mehak, Haleema Iqbal, Nisar, Nayab, Saifullah  (2026) SGLT2 INHIBITORS BEYOND DIABETES A RETROSPECTIVE AUDIT OF PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION.  SYNAPSES: INSIGHTS ACROSS THE DISCIPLINES.       
document_url: https://arxiv.universalpublishings.com/id/eprint/87757/1/34374.pdf